ViroNovative BV is a Dutch company that was spun off from Erasmus Medical Center to commercialize patents related to the human metapneumovirus (hMPV). The company is developing diagnostics, vaccines, antibodies, and antivirals for detecting, preventing, and treating hMPV infection. ViroNovative has licensed hMPV diagnostic technology to over 14 diagnostic companies. It also owns new intellectual property for hMPV vaccines, antibodies, and use of hMPV as a vaccine vector that it is looking to co-develop with partners. HMPV is a major cause of respiratory infections worldwide with significant disease burden and economic impact.
This is a presentation for all the people who are unaware about COVID-19.
COVID-19 = Corona Virus Disease 2019. Please like and share my presentation.
Presentation by:-
C. S. Nelson
VI - E
D.A.V Boys Senior Secondary School.
D.A.V Group of School.
This is a presentation for all the people who are unaware about COVID-19.
COVID-19 = Corona Virus Disease 2019. Please like and share my presentation.
Presentation by:-
C. S. Nelson
VI - E
D.A.V Boys Senior Secondary School.
D.A.V Group of School.
The SARS-Cov2 is highly pathogenic and has spread very rapidly.
Here we have tried to present an overview of the prevailing COVID-19 situation in terms of health impact, pathophysiology, clinical manifestations, diagnosis, management, emergency responses and preparedness.
The research literature is growing rapidly and hopefully it will help in finding an effective vaccine (many in trials) and the best practice for the management and treatment of symptomatic cases.
The health, social and economic impacts would be high by this global killer.
We should be able to learn lessons and hopefully we will be more prepared for any such event in future.
“You can download this product from SlideTeam.net”
Spread awareness about the pandemic using the impressive visuals of our Corona Virus Disease 19 Powerpoint Presentation Slides. The easy-to-follow content of coronavirus PPT theme assists you to convey information to the audience of all ages, shapes, and sizes. This COVID 19 PowerPoint slideshow will help you explain the age risk factors, symptoms, and prevention methods concisely. Impactful data visualization tools like infographics in this novel coronavirus pneumonia PPT template enables you to effortlessly demonstrate sophisticated data. Compare the spread, incubation rate of coronavirus against other pandemics, and portray mortality rate through this corona PowerPoint presentation. Present crucial information like how long the virus lasts on different surfaces, and risk factors through this COVID PPT slideshow. Our 2019-nCoV acute respiratory disease PowerPoint theme helps you to illustrate the outbreak of the pandemic continent-wise. Download severe pneumonia with novel pathogens PPT template to explain crucial information related to the pandemic like effects on the stock market. https://bit.ly/3IN6j4F
guidelines of WHO on Coronavirus, structure of coronavirus, prevention and ongoing researches for COVID-19, what does pandemic mean, role of immune system for coronavirus and how to improve general immunity, how COVID-19 got its name, about SARS-CoV-2, when and how to use mask and dispose it off, myths related to coronavirus, studies going on in Oxford University for vaccine of COVID-19 from chimpanzee called as ChAdOx1 nCoV-19
COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), a strain of coronavirus. The first cases were seen in Wuhan, China in December 2019 before spreading globally. The current outbreak was recognized as a pandemic on 11 March 2020.
The non-specific imaging findings are most commonly of atypical or organizing pneumonia, often with a bilateral, peripheral, and basal predominant distribution. No effective treatment or vaccine exists currently (March 2020).
Corona virus current scenario (theoretical outlook)Dr. sreeremya S
Corona virus(COVID-19) is RNA virus. Which has proved to be pandemic.It causes respiratory disease called Severe Acute Respiratory Syndrome(SARS). Currently it is a deadly disease which is killing hundreds of people day by day from late 2019 to till date. There is only few studies regarding the corona virus infection in animals. Studies are still progressing to find remedies like variolation, RNA silencing or boosting human interferon’s to decrease the affect of the disease.
covid-19 disease or novel corona virus disease or sars-cov 2 information includes all about virology,patho physiology, taxonomy of virus, taxonomy of intermediary host pangolin,and preventive measures needed to be followed by public etc, in a most possible concised manner illustrated in this presentation.
Upsurge of Cases of Lichen Planus in Iraqi Population in Baghdad City with Fr...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
The SARS-Cov2 is highly pathogenic and has spread very rapidly.
Here we have tried to present an overview of the prevailing COVID-19 situation in terms of health impact, pathophysiology, clinical manifestations, diagnosis, management, emergency responses and preparedness.
The research literature is growing rapidly and hopefully it will help in finding an effective vaccine (many in trials) and the best practice for the management and treatment of symptomatic cases.
The health, social and economic impacts would be high by this global killer.
We should be able to learn lessons and hopefully we will be more prepared for any such event in future.
“You can download this product from SlideTeam.net”
Spread awareness about the pandemic using the impressive visuals of our Corona Virus Disease 19 Powerpoint Presentation Slides. The easy-to-follow content of coronavirus PPT theme assists you to convey information to the audience of all ages, shapes, and sizes. This COVID 19 PowerPoint slideshow will help you explain the age risk factors, symptoms, and prevention methods concisely. Impactful data visualization tools like infographics in this novel coronavirus pneumonia PPT template enables you to effortlessly demonstrate sophisticated data. Compare the spread, incubation rate of coronavirus against other pandemics, and portray mortality rate through this corona PowerPoint presentation. Present crucial information like how long the virus lasts on different surfaces, and risk factors through this COVID PPT slideshow. Our 2019-nCoV acute respiratory disease PowerPoint theme helps you to illustrate the outbreak of the pandemic continent-wise. Download severe pneumonia with novel pathogens PPT template to explain crucial information related to the pandemic like effects on the stock market. https://bit.ly/3IN6j4F
guidelines of WHO on Coronavirus, structure of coronavirus, prevention and ongoing researches for COVID-19, what does pandemic mean, role of immune system for coronavirus and how to improve general immunity, how COVID-19 got its name, about SARS-CoV-2, when and how to use mask and dispose it off, myths related to coronavirus, studies going on in Oxford University for vaccine of COVID-19 from chimpanzee called as ChAdOx1 nCoV-19
COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), a strain of coronavirus. The first cases were seen in Wuhan, China in December 2019 before spreading globally. The current outbreak was recognized as a pandemic on 11 March 2020.
The non-specific imaging findings are most commonly of atypical or organizing pneumonia, often with a bilateral, peripheral, and basal predominant distribution. No effective treatment or vaccine exists currently (March 2020).
Corona virus current scenario (theoretical outlook)Dr. sreeremya S
Corona virus(COVID-19) is RNA virus. Which has proved to be pandemic.It causes respiratory disease called Severe Acute Respiratory Syndrome(SARS). Currently it is a deadly disease which is killing hundreds of people day by day from late 2019 to till date. There is only few studies regarding the corona virus infection in animals. Studies are still progressing to find remedies like variolation, RNA silencing or boosting human interferon’s to decrease the affect of the disease.
covid-19 disease or novel corona virus disease or sars-cov 2 information includes all about virology,patho physiology, taxonomy of virus, taxonomy of intermediary host pangolin,and preventive measures needed to be followed by public etc, in a most possible concised manner illustrated in this presentation.
Upsurge of Cases of Lichen Planus in Iraqi Population in Baghdad City with Fr...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Author: Dr Christa Maria Joel
Module: Principles of Infection and Disease Control
Supervisor: Dr William Mackay Gordie and Ms Fiona Hernandez
University of the West of Scotland
List of viruses causing Cancer:
Human papillomavirus (HPV)
Hepatitis C Virus
Hepatitis B Virus
Human Immunodeficiency Virus (HIV)
Human Herpes Virus 8 (HHV - 8)
Human T lymphocytic Virus (HTLV-1)
Epstein-Barr virus (EBV)
Merkel Cell Polyomavirus
Clinical Epidemiological Study of Secondary Syphilis - Current Scenarioiosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Role of Mukta Pishti in the Management of Hyperthyroidism
Vino final powerpoint
1.
2. Please visit us at: http://www.vironovative.com/
• ViroNovative BV is a limited liability company established under Dutch Law as a
spin-out from the Department of Virology Erasmus Medical Center Rotterdam, The
Netherlands
• The company was started by Eric Claassen and Prof. Dr. Ab Osterhaus as a
dedicated vehicle for expanding and commercializing the patent portfolio
concerned with the human meta-pneumo virus (hMPV)
• ViroNovative BV is co-developing diagnostics, vaccines, antibodies and antivirals
for the detection, prevention and treatment of hMPV infection. Since its inception
the company has licensed out technology for diagnostics to over 14 major
diagnostic companies
• Furthermore, new IP concerning vaccines, antibodies and the use of hMPV as a
viral vaccine vector (e.g. for RSV) was developed and filed, for this we are actively
looking for co-development partners. All relevant background and foreground IP is
owned by ViroNovative BV
3. Fields of Use and Subjects of the
Patent Estate:
• Diagnostic use of hMPV for all types of assays (multiple licensors)
• Development of an hMPV vaccine
• Development of an hMPV therapeutic antibody (passive
immunization)
• Development of an anti-viral specific for hMPV
• Use of hMPV as a respiratory viral vaccine vector (for e.g. RSV/PIV/Flu)
4. • Globally, infectious diseases are responsible for nearly 30% of all deaths
worldwide; more than 15 million people die every year
• Acute respiratory infections (ARI) continue to be the leading cause of
acute illnesses worldwide and remain the most important cause of infant
and young children mortality
Fig. Global causes of death
Source: WHO (2009)
Infectious Diseases (Millions)
Respiratory Infections 3,96
HIV/AIDS 2,77
Diarrhoeal Diseases 1,80
Tuberculosis 1,56
Vaccine Preventable Childhood
Diseases
1,12
Malaria 1,27
STD 0,18
Meningitis 0,17
Hepatitis B and C 0,16
Tropical Parasitic Diseases 0,13
Dengue 0,02
Other 1,76
5. Top 10 causes of death worldwide 2011
Source: WHO
Infectious diseases are responsible for 3 out of 10
leading causes of death in 2011
6. hMPV + RSV form majority disease burden
(68%!) in respiratory viral infections
Notable change in significance
recognition of HMPV:
• ~19 % of RTIs caused by known
viruses
• Classically hMPV was (and is)
mistaken for RSV
• This emphasizes the importance of
various diagnostic tools
• Virus Specific treatment is essential
and will lead to:
• Clinical cost reduction
• Less disease (vaccine)
• Larger and emerging markets
Entero
5%
Rhino
11%
Adeno
3%
PIV3
3%
PIV1
3%
Flu B
3%
Flu A
4%
hRSV
49%
hMPV
19%
8. • Annual cost for treatment of viral respiratory tract infections (vRTI) in USA
and EU estimated at 50 billion USD
• hMPV accounts for 5-10% of vRTI
• Incidence:
- 6% in children and healthy adults and elderly
- 10% (regional differences) in at risk groups
• Sales could exceed 1B USD annually at full market penetration in USA and EU
Therapeutic Market: Estimated
9. hMPV
• While hMPV has traditionally been associated with upper respiratory tract
infection, it is now also recognized as a major cause of lower respiratory
tract infection in children in several geographical regions
• Recent studies have shown that hMPV accounted for 5-15% of all
hospitalizations for acute respiratory infection, while in acute respiratory
tract infection (ARTI) in young children, infants and other high-risk
populations hMPV is the leading cause of with underlying medical
conditions such as prematurity, asthma, cardiopulmonary disease, and
immune-compromised patients
10. hMPV and RSV Facts
• In the past few decades, many etiological agents of respiratory
tract illnesses (RTI) have been identified, however a proportion
remains with unknown causative pathogen.
• HMPV was uncovered in 2001 by van den Hoogen, BG. Jong, JC.
Groen, J. Kuiken, T. de Groot, R. Fouchier, RA. And Osterhaus AD
as published in Nature Medecine; A newly discovered human
pneumovirus isolated from young children with respiratory tract
disease
• Initially 28 epidemiological unrelated RTI nasopharyngeal aspirate
samples, collected over a 20 year period, contained hMPV
isolates.
• HMPV is a newly discovered respiratory virus of the family
Paramyxoviridae.
• Genetic and phylogentic research has shown that hMPV is closely
related to respiratory syncytial virus (RSV). Further research
indicates they are also related in the clinical setting.
• Clinical signs and symptoms are typically non-specific, and may
include rhinorrhea, sore throat, sneezing, cough, fever, aching
muscles and limbs, headache, and malaise.
• Although the highest burden of hMPV is in young children, it has
become clear that hMPV and RSV infections are responsible for an
important proportion of RTI across all age groups. In a prospective
cohort of nearly 1.400 adult hospitalisations for RTI, hMPV and
RSV accounted for 8.0% and 10.5% of the illnesses respectively.
Moreover, the proportions of hMPV-and RSV-infected patients
requiring ICU admission (13% and 15%) or dying (7% and 8%)
were similar for both viruses
• HMPV can be distinguishable from RSV and other RTIs …
– …
Fig. Comparing clinical symptoms and frequency for hMPV, RSV and Influenza
Source: Walsch (2008) and Falsey (2003)
11. hMPV and RSV: Benchmark
AGE DISTRIBUTION OF
hMPV PATIENTS
SIMILAR TO THAT OF
RSV PATIENTS
SEASONAL
DISTRIBUTION OF hMPV
INFECTIONS IS SIMILAR
TO THAT OF RSV
12. hMPV in adults
• In adults of all ages, hMPV is a common infection, and can result in serious infection
that requires hospitalization due to; acute bronchitis, COPD exacerbations, and
pneumonia
• Average lengths of hospitalization for hMPV-infected younger adults was 9
days, with 13.2% requiring ICU. Elderly adults remain ill for an average of 17 days
• Studies indicate the association of hMPV infection with hospitalisation for acute
respiratory tract symptoms in elderly adults
• HMPV infection was similar to 5.5% annual average infection rate for RSV, and
greater than that of influenza A (2.4%)
• Several documented outbreaks of hMPV have occurred in long term care
facilities, with mortality of up to 50%
Annual Incidence/ % Study Cohort
13.1 Adults aged 19-40 with acute RTI during winter
5.9 Healthy adults >65 with acute RTI during winter
9.1 High risk adults with acute RTI during winter
8.5 Adult patients hospitalized with acture RTI during
winter
Table. Incidence of hMPV in elderly in the US
Source: Walsch et al (2008)
13. hMPV in children
• Among infants and children aged less than 3 years in Northern Spain, the incidence
rate of hospitalization for hMPV was calculated at 2.6 per 1,000 children, which was
higher than the incidence of influenza and PIV
• Infection with hMPV in children varies between 5-37% incidence in patients with
respiratory tract symptoms
Author Country % children with RTI
infected with hMPV
Reference
Sung Taiwan 27.1 J Microbil, Immun and Infect 2011; 44: 184-190
Boivin Canada 6 Emerg Infect Dis 2003; 9: 634-40
Esper USA 6.4 Pediatrics. 2003; 111: 1407-10
Freymouth France 6.6 Pediatr Infect Dis. 2003;22:92-4
Jartti Finland 8 Lancet. 2002;360:1393-1394
Maggi Italy 37, 7, 43 J Clin Microbiol. 2003;41:2987-2991
Peiris Hong Kong 5.5 Emerging Infect Dis. 2003;9:268-33
Van den Hoogen Netherlands 7 J Infect Dis. 2003;188:1571-7
Viazov Germany 17.5 J Clin Microbiol. 2003;41:3043-5
Table. Incidence of hMPV in children
14. hMPV, major pathogen in respiratory
complications
hMPV Patient
Groups
Young
Children <5
years
Elderly
Lung
Transplant
Patients
Patients with
COPD/
Asthma
Immuno-
compromised
Patients
Patients with
hematologic
malignancies
15. Huge Economic Impact leads to Value
• Potential value of vaccination for hMPV is significant due to high medical costs
• Given that the clinical manifestations and supportive treatment of hMPV is closely related to those of RSV, literature of
hospitalizations costs as a result of RSV was analysed
• Mean costs are estimated at € 2,929 per hospitalization for RSV
• Some studies have estimated the cost of a paediatric hospitalization for influenza at between $3,000 and $4,000 which
includes all medical costs regarding to treatment of influenza clinically
• In Europe, there are around 31.000 children hospitalized annually due to hMPV-associated disease
– Mean hospital duration: 6.5 days
– This means that the annual economic burden of hospitalized children due to hMPV infections is (6.5* €3,000-4,000) *
cases in EU/US = total burden hospitalized children due to hMPV infections
• Total economic impact of non–influenza related vRTI approaches $40 billion annually in the United States (direct costs, $17
billion per year; and indirect costs, $22.5 billion per year)
• The next assumptions are:
– When vRTIs in the US costs around 17 (300 mln people) billion per year on direct costs, the burden for the EU is (700
mln people) approximately twice as much as those for the US (> 34 billion)
– This means that the burden of disease of vRTI in the EU and US market is 51 billion
– HMPV accounts for 5-10% of the viral respiratory diseases
– The burden of disease per year is € 2.5 - € 5.1 billion per year
Region Annual Economic
Impact
Per Patient Costs
Hospitalization
Study Design References
USA $ 500 Mln
(admission cost)
€ 3799 Bronchiolitis-related
hospitalizations
Pellier et al. 2005
USA $ 700 Mln
(total burden)
- Annual RSV burden Paramore et al. 2004
Germany € 213 Mln
(LRTI burden)
€ 2579 LRTI hospitalizations Ehlken et al. 2005
The
Netherlands
€ 2,7 Mln
(RSV burden)
€ 3110 Annual RSV burden Rietveld et al. 2004
Table showing estimation of RSV hospitalization burden
16. Source: DMHC2601
Table showing estimation of RSV hospitalization burden
Diagnostic
testing
Patient presents to GP
/ family physician
Emergency room
admission, admission after
outpatient specialist
visit, infection acquired in
hospital
Admission to
hospital
Treated
empirically
Community
Patient managed by
hospital specialist or
attending physician
Prescription of
therapy
Onset of
symptoms
Patient self-
medicates, sympto
ms resolve
Symptomatic
treatment
Non-pharmacological
treatment
Condition worsens
Treated
empirically
Diagnostic
testing
Condition
worsens
Condition
worsens
Hospital
Trigger point 1: Pharmaceutical companies should
attempt to increase awareness of RVIs among
physicians and the general public
Trigger point 2: Use of laboratory diagnostics can
determine the causative virus and dictate treatment
choice
Trigger point 3: Influence initial brand choice
1
2
3
Prescription of
therapy
1
3
3
3
3
2
2
Point of Care diagnostics
open up other and larger markets!
18. Value of hMPV diagnostics business
stems from multiple sources
Control of Market
• Control of hMPV market: value €?m
– Market size potential equivalent to that of
RSV at €30-40m with ~5-10% CAGR
– Broad protection from competing
diagnostics for hMPV
– Control of licensing
• Significant licensing revenues
• Synergies: value = €?m
– Development, manufacturing, marketing
and sales
Competitive Advantage
• Competitive advantage in respiratory pathogens
market: value €?m
– No other respiratory virus
subject to broad protection from
competing diagnostics
– Leverage hMPV to gain share of
diagnostics to other respiratory pathogens
• eg RSV (market size €30-40m with
~5-10% CAGR)
• Influenza (market size considerably
greater than RSV)
Synergies
19. • Currently, there are no approved therapeutics or vaccines for PIV or hMPV
infections, despite a high burden and strong unmet need.
Mis-diagnosis of hMPV results in mis-prescription of antibiotics and corticosteroids
Virazole (Ribavarin)
has poor efficacy, undesirable
safety profile, and an
inconvenient mode of
administration for RSV
treatment
No vaccine
available for RSV
Efficacious and safe
RSV treatments
Two key unmet needs
Therapies with strong efficacy
against severe disease
New drugs to combat
growing resistance
Development of
new oral drugs
Increasinglevelofimportance
Parenteral agents for
hospitalized patients
Influenza RSV, PIV, and hMPV
RSV vaccine
PIV and hMPV
No Approved Products
Editor's Notes
Vironovative, as coordinating member of VIRGO, was also the winner of the one million euro Dutch NGI Valorisation Award 2008-9 for “Excellent long term academic industrial relationships”.
Source: WHO (2009): WHO (2004): Williams et al. J Infect Dis (2010): Fabbiani, et al. J Med Virol (2009)
Source: van de Hoogenet al. Nature Medecine (2001): Williams et al. J Infect Dis (2006): Manohaet al. J ClinVirol (2007): Walsh et al. Arch Intern Med (2008): Hall et al. N Engl J Med (2009): Falseyet al. N Engl J Med (2005)
Source: Falseyet al. Vaccine (2010): Boivinet al. Clin Infect Dis (2007): Walsh et al. Arch Intern Med (2008): Cillaet al. Epidemiol. Infect. (2009): Williams et al. J Infect Dis (2010) Two recent studies provided hospitalization rates for children. Cilla et al. (2009) found a higher hospitalization rate than in William et al. (2010). This may be due the fact that the population in the study of Cilla was slightly younger
Source: Falseyet al. Vaccine (2010): Boivinet al. Clin Infect Dis (2007): Walsh et al. Arch Intern Med (2008): Cillaet al. Epidemiol. Infect. (2009): Williams et al. J Infect Dis (2010). Sung et al.J Microbil,Immunand Infect (2011)Two recent studies provided hospitalization rates for children. Cilla et al. (2009) found a higher hospitalization rate than in William et al. (2010). This may be due the fact that the population in the study of Cilla was slightly younger
Source: Keren et al. (2006): Sloots, et al. (2006): Fendrick, et al. (2003)
Source: Keren et al. (2006): Sloots, et al. (2006): Fendrick, et al. (2003)